Being a PFM just got better
Published September 27, 2024
APC is launching five new benefits for our Pharmacy-Facility members to help you and your business prosper.
APC News
Thompson elected, Browning appointed
Published September 27, 2024
Two changes to boards of directors were made last week.
HIPAA, schmipaa — Lilly is at it again
Published September 20, 2024
Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company.
Settlement reached in Evexias suit against FDA
Published September 20, 2024
A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list.
Rochefort receives Malmberg Award
Published September 20, 2024
David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor.
For they’re jolly good Fellows*
Published September 20, 2024
This year’s CCH featured the induction of seven new APC fellows.
Be fruitful and multiply … our messaging, that is
Published September 13, 2024
Even if you didn't attend Compounders on Capitol Hill, you can multiply the effect of those Hill visits.
APC supports upcoming DEA guidance on constructive transfer
Published September 13, 2024
Some good news: DEA is set to issue much-needed new guidance on constructive transfer.
503Bs: FDA has questions, and so do we (do you?)
Published September 13, 2024
FDA has requested comments on the challenges and opportunities faced by compounding outsourcing facilities.
Meet our compounding defenders, guardians and champions (Oh my!)
Published September 13, 2024
Here’s a big thank you to our Package Deal investors.
PCAC to discuss 503A bulks list substances
Published September 6, 2024
FDA’s Pharmacy Compounding Advisory Committee has announced that it will hold two meetings (!) between now and year-end to consider recommending several bulk drug substances to the 503A Bulks List.
Welcome, new PFMs!
Published September 6, 2024
We’ve added 31 Pharmacy-Facility Members since February!
Let’s talk about that Lilly announcement
Published August 30, 2024
There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats.
Our response to the op-ed in The Hill
Published August 30, 2024
The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO.
A new bronze corporate patron
Published August 30, 2024
A big welcome to Ro, APC’s newest tier-level corporate patron!
Compounding post-Chevron
Published August 23, 2024
At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.”
503B sourcing: our state-by-state analysis
Published August 23, 2024
Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource.
What we’ll be talking about at CCH
Published August 23, 2024
When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.
NEW: Shortage Drug Compounding Best Practices
Published August 15, 2024
If you compound GLP-1s or any drug that’s in shortage, you need to read this. It’s one click and just a few pages — but they’re critical pages.
APC releases “best practices” guide for compounding drugs in shortage, including GLP-1s
Published August 15, 2024
A new document provides compounding pharmacies best practices for dispensing customized medications that are in shortage, including GLP-1 drugs such as semaglutide and tirzepatide.
When “available” doesn’t mean “available”
Published August 9, 2024
Mounjaro is available, crows Eli Lilly. Ditto for Zepbound! Novo Nordisk reports the same for Ozempic and Wegovy. Except for one small thing: “Available” is very, very different than “out of shortage.”
15 hours that will grow your expertise (and build your patients’ trust)
Published August 9, 2024
You and your team need to operate at the highest ethical and legal standards, and we don’t need to tell you why. Problem: Those standards are complex and constantly changing. If you’re new to compounding, they can be daunting.
Board nominations are open: APC & Pharmacy Compounding Foundation
Published August 6, 2024
We’re seeking passionate, informed, influential compounding leaders to help guide our alliance as members of the APC Board of Directors and of the Pharmacy Compounding Foundation.
Have you seen the new Compounding.com?
Published August 6, 2024
The first iteration of Compounding.com 2.0 is up and live, but there’s much more to come. Check it out and watch it expand!
Bormel: Yes, GLP-1s can be compounded
Published August 6, 2024
In an interview with Politico last week, Gail Bormel, the director for the FDA’s Office of Compounding Quality and Compliance, once again provided a clear reading of FDA’s ‘essentially a copy’ guidance.
Tirzepatide out of shortage?
Published August 6, 2024
Eli Lilly says that Zepbound will come out of shortage in the next few days, according to news reports, which suggest it could be a problem for compounded versions. Perhaps that’s how Lilly is spinning it.
California BOP pauses new compounding regs
Published August 6, 2024
After a concerted effort by APC, its members, and a coalition of others, the California Board of Pharmacy has postponed its proposed new restrictions on compounded medications after a long and detailed meeting on July 31.
You win some … (NPR)
Published July 31, 2024
NPR’s Sydney Lupkin continues to achieve balance and accuracy in her reporting on compounding, and we’re grateful for it.
… you lose some (Bloomberg)
Published July 31, 2024
Sometimes, though, even with a lot of phone calls, the message doesn’t get through. Such was the case with Bloomberg.
What’s up with the MOU?
Published July 31, 2024
With all the coverage of GLP-1s, the proposed MOU between states and FDA has faded into the background, but it’s still out there, and APC is keeping track of developments.
